# Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation (XSDR)

**Source:** https://fundology.uk/fund/xsdr · ISIN LU0292103222 · Data: TradingView (LSE closes and returns, delayed), issuer documents, ONS CPIH, FCA FIRDS

## At a glance

> Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.

As of 30/09/2026, XSDR (Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation, ISIN LU0292103222) closed at £190.11 on the London Stock Exchange. Its ongoing charge is 0.20% a year (about £20 on £10,000). Over the five years to 30/09/2026 its total return was +23.8%, or −3.2% after UK CPIH inflation.

## Summary

Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation is an exchange-traded fund (ETF) from Xtrackers, launched in 2007. It tracks the MSCI Europe Health Care ESG Screened 20-35 Index - EUR — large and medium-sized European companies. You buy and sell it through a share-dealing account or platform during stock-market hours, like a share. Its ongoing charge is 0.2% a year — about £20 a year on every £10,000 invested, taken from the fund's value rather than billed to you. Income from its investments is reinvested inside the fund, so it shows up as a rising price rather than cash paid to you.

Latest close: **£190.11** (30/09/2026).

## Key facts

| Fact | Value |
|---|---|
| Ticker (LSE) | XSDR |
| ISIN | LU0292103222 |
| Category | Healthcare |
| Type | ETF |
| Provider | Xtrackers |
| Tracks | MSCI Europe Health Care ESG Screened 20-35 Index - EUR |
| Income | Accumulating |
| Ongoing charge | 0.20% a year (£20 per £10,000) |
| Fund size | £202m |
| Launched | 2007 |
| Domicile | Luxembourg |

## Past returns (periods to 30/09/2026)

After the fund's ongoing charges. "Income reinvested" is total return; "price only" leaves out income paid out. Real returns are after ONS CPIH inflation.

| Window | Return | After CPIH inflation | Measured as |
|---|---|---|---|
| 1 year | +8.41% | +5.01% | income reinvested |
| 3 years | +7.03% | -3.42% | income reinvested |
| 5 years | +23.79% | -3.23% | income reinvested |

Returns: TradingView (delayed data). Inflation: ONS CPIH, latest month published.

## Charges compared with similar funds

Ongoing charge of Xtrackers SICAV - Xtrackers MSCI Europe Health Care Screened UCITS ETF-1C- Capitalisation 0.20% a year, as of 01/10/2026: 10 of the 17 other healthcare funds charge more, 0 the same and 7 less (share classes counted once).

## Charges & eligibility

- Ongoing charges figure (OCF): **0.20%** per year
- ISA eligible: yes
- SIPP eligible: yes

## Top holdings

Largest positions (as of 01/10/2026):

| Holding | Weight |
|---|---|
| Roche Ps Par | 16.84% |
| Novartis | 15.20% |
| AstraZeneca | 14.22% |
| Novo Nordisk · Class B | 7.04% |
| GSK | 5.68% |
| Sanofi | 5.07% |
| Argenx | 3.45% |
| Bayer | 3.12% |
| Lonza Group | 2.81% |
| EssilorLuxottica | 2.72% |

## Where it invests

Shares of the whole fund. Bonds, cash and positions the source does not classify are shown as they come, not guessed.

### By sector

Added up from the holdings Xtrackers publishes, as of 01/10/2026.

| Sector | Weight |
|---|---|
| Health Care | 99.9% |
| unknown | 0.1% |

### By country

Added up from the holdings Xtrackers publishes, as of 01/10/2026.

| Country | Weight |
|---|---|
| Switzerland | 43.1% |
| United Kingdom | 22.7% |
| France | 9.1% |
| Denmark | 8.9% |
| Germany | 7.2% |
| Netherlands | 5.1% |
| Belgium | 1.9% |
| Finland | 0.6% |
| Other countries | 1.4% |
| Not classified | 0.0% |

### By type of asset

Added up from the holdings Xtrackers publishes, as of 01/10/2026.

| Type of asset | Weight |
|---|---|
| Equity | 100.0% |
| Cash and money market | 0.1% |

All 42 holdings: https://fundology.uk/fund/xsdr/holdings

---

We show information. We are not financial advisers, not authorised by the FCA, and never recommend specific investments.

Capital at risk. Past performance is not a guide to future returns. The value of investments can fall as well as rise.